Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Haoxi Health TechnologyHAO -11.71%21 Debt-to-EBITDA is -0.12 as of Dec. 2025. GuruFocus rates HAO with a GF Score™ of 21/100. The stock has 5 warning signs investors should review. Among 682 Media - Diversified companies, Haoxi Health Technology ranks worse than 146627.42% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Haoxi Health Technology's Debt-to-EBITDA or its related term are showing as below:
HAO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.81 Med: 0.7 Max: 1.86
Current: -0.81
During the past 5 years, the highest Debt-to-EBITDA Ratio of Haoxi Health Technology was 1.86. The lowest was -0.81. And the median was 0.70.
HAO's Debt-to-EBITDA is ranked worse than 100% of 682
companies
in the Media - Diversified industry
Industry Median: 1.59
vs HAO: -0.81
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Haoxi Health Technology Debt-to-EBITDA Related Terms
Haoxi Health Technology Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAO vs BAOS, DBMM, DRCT: Debt-to-EBITDA Comparison
For the Advertising Agencies subindustry, Haoxi Health Technology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haoxi Health Technology Debt-to-EBITDA vs Media - Diversified Industry
For the Media - Diversified industry and Communication Services sector, Haoxi Health Technology's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Haoxi Health Technology's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Haoxi Health Technology (HAO) has a Debt-to-EBITDA of -0.12 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Haoxi Health Technology. According to the industry distribution chart, Haoxi Health Technology ranks #999999 out of 682 companies in the Media - Diversified industry.
Is Haoxi Health Technology's Debt-to-EBITDA too high?
Haoxi Health Technology's current Debt-to-EBITDA is -0.12. Based on the distribution chart, Haoxi Health Technology ranks #999999 out of 682 companies in the Media - Diversified industry, which is in the bottom quartile relative to peers. Overall, Haoxi Health Technology has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Haoxi Health Technology's Debt-to-EBITDA compare to BAOS and DBMM?
According to the Media - Diversified industry distribution chart, Haoxi Health Technology ranks #999999 out of 682 companies for Debt-to-EBITDA. This places Haoxi Health Technology in the lower half of its industry. The industry median Debt-to-EBITDA is 1.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Media - Diversified company?
The median Debt-to-EBITDA among Media - Diversified companies is 1.59, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Haoxi Health Technology. For the Media - Diversified industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haoxi Health Technology's current Debt-to-EBITDA is -0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haoxi Health Technology stock overvalued right now?
Haoxi Health Technology (HAO) has a current Debt-to-EBITDA of -0.12. The current Debt-to-EBITDA is -0.12. Haoxi Health Technology's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Haoxi Health Technology (HAO), the current Debt-to-EBITDA is -0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Haoxi Health Technology Ltd is an online marketing solution provider in China, with an advertiser client base mainly in the healthcare industry. The company offers services that include planning, producing, placing, and optimizing online ads especially online short video ads, to help its advertisers acquire, convert, and retain ultimate consumers on various online media platforms. It places advertisements on popular digital platforms such as Toutiao, Douyin, WeChat, and Sina Weibo through media partners. Revenue is generated by providing comprehensive online marketing solutions. The company's operations center on digital advertising via mainstream video and social media channels in the Chinese market.
21GF Score
Get the complete analysis for HAO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAO has been successfully added to your 
